Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4722 related articles for article (PubMed ID: 29861325)

  • 1. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
    Liu G; Rui W; Zheng H; Huang D; Yu F; Zhang Y; Dong J; Zhao X; Lin X
    Eur J Immunol; 2020 May; 50(5):712-724. PubMed ID: 31981231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
    Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
    Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
    Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive cell transfer therapy for hepatocellular carcinoma.
    Zhang R; Zhang Z; Liu Z; Wei D; Wu X; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):3-11. PubMed ID: 30659408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
    Lu F; Ma XJ; Jin WL; Luo Y; Li X
    Front Immunol; 2021; 12():690565. PubMed ID: 34054880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
    Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
    Front Immunol; 2022; 13():830292. PubMed ID: 35211124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
    Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
    Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
    Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
    J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 237.